830842P

08:0 PA

1,2-dioctanoyl-sn-glycero-3-phosphate (sodium salt), powder

• Synonym(s): PA(8:0/8:0)
• Empirical Formula (Hill Notation): C₁₉H₃₆O₈PNa
• CAS Number: 321883-54-9
• Molecular Weight: 446.45
• UNSPSC Code: 51191904
• NACRES: NA.25

Properties

• Assay: >99% (TLC)
• form: powder
• packaging: pkg of 1 × 10 mg (830842P-10mg); pkg of 1 × 25 mg (830842P-25mg)
• manufacturer/tradename: Avanti Polar Lipids 830842P
• lipid type: cardiolipins; phospholipids
• shipped in: dry ice
• storage temp.: −20°C
• SMILES string: [H][C@@](COP([O-])(O)=O)(OC(CCCCCCC)=O)COC(CCCCCCC)=O.[Na+]
• InChI: 1S/C19H37O8P.Na/c1-3-5-7-9-11-13-18(20)25-15-17(16-26-28(22,23)24)27-19(21)14-12-10-8-6-4-2;/h17H,3-16H2,1-2H3,(H2,22,23,24);/q;+1/p-1/t17-;/m1./s1
• InChI key: ZNDNSOYDPUTHKQ-UNTBIKODSA-M

Description

General description

Phosphatidic acid is obtained from glycerophospholipid with the help of phospholipase D. 08:0 PA/1,2-dioctanoyl-sn-glycero-3-phosphate (C8-PA) is an mammalian target of rapamycin (mTOR) activator.

Application

08:0 PA may be used to activate p-mTOR in order to assess whether the observed apoptotic effect of histone deacetylase inhibitors (HDACIs) is related to mammalian target of rapamycin (mTOR) pathway signaling.

Biochem/physiol Actions

Phosphatidic acid might serve as a modulator of phagocyte respiratory burst. It also acts as a precursor of diacylglycerol and lysophosphatidic acid. 08:0 PA/C8-PA has the ability to affect the phosphorylation of mammalian target of rapamycin (mTOR) and the viability of gallbladder carcinoma cells, that are treated with histone deacetylase inhibitors (HDACIs).

Packaging

5 mL Clear Glass Sealed Ampule (830842P-10mg)

5 mL Clear Glass Sealed Ampule (830842P-25mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Safety Information

• Storage Class Code: 11 - Combustible Solids